Alpharix Tetra

Alpharix Tetra (also known as Fluarix Tetra) is a quadrivalent inactivated split-virion influenza vaccine developed and manufactured by GSK. It is designed to provide broad protection against seasonal influenza by including antigens from four different strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The vaccine works by inducing the production of hemagglutination-inhibition (HI) antibodies that neutralize the virus and prevent infection. It is indicated for active immunization of adults and children from 6 months of age. The specific mention of University Hospital, Ghent refers to its role as the lead sponsor for the Phase 4 BioVacSafe study, which utilized this vaccine to investigate biomarkers of innate and adaptive immune activation following vaccination.

Brand names

Alpharix TetraFluarix TetraInflusplit Tetra

Other names

seasonal quadrivalent influenza vaccinequadrivalent inactivated influenza vaccineQIV